Healthcare News

Cambridge, UK, 24th April 2026 - Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces the...

SANDWICH, United Kingdom, April 24, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), will...

EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its “totality of evidence” approachcentral photographic review and validated disease...

Vistin Pharma ASA: First quarter 2026 financial results Oslo, Norway, 24th of April 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2026. First quarter...

Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded...

Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded...

IBA réunit les experts les plus renommés en protonthérapie venant des institutions de soins oncologiques les plus prestigieuses. Louvain-la-Neuve, Belgique, le 24 avril 2026 – IBA (Ion Beam...

IBA gathers the most knowledgeable proton therapy experts coming from the most prestigious cancer care institutions. Louvain-La-Neuve, Belgium, April 24, 2026 – IBA (Ion Beam Applications S.A.,...

Agomab Therapeutics NV today reported financial results for the full year period ended December 31, 2025, and confirmed its outlook for 2026.

WINNIPEG, Manitoba, April 23, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its fourth quarter and full year 2025 financial...